These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 36715093)
1. A severe cerebral infarction associated with giant cell arteritis, which developed during tocilizumab therapy and was successfully treated with intravenous cyclophosphamide. Suzuki K; Akiyama M; Ishigaki S; Kondo Y; Saito S; Kikuchi J; Hanaoka H; Kaneko Y Mod Rheumatol Case Rep; 2023 Jun; 7(2):453-457. PubMed ID: 36715093 [TBL] [Abstract][Full Text] [Related]
2. Tocilizumab for giant cell arteritis: an amazing result. Işık M; Kılıç L; Doğan İ; Calgüneri M Rheumatol Int; 2013 Nov; 33(11):2961-2. PubMed ID: 22965672 [TBL] [Abstract][Full Text] [Related]
6. Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report. Cho YM; El Khoury L; Paramo J; Horowitz DM; Li JY; Kello N BMC Musculoskelet Disord; 2023 May; 24(1):382. PubMed ID: 37189114 [TBL] [Abstract][Full Text] [Related]
7. Treatment of giant cell arteritis. González-Gay MÁ; Pina T; Prieto-Peña D; Calderon-Goercke M; Gualillo O; Castañeda S Biochem Pharmacol; 2019 Jul; 165():230-239. PubMed ID: 31034796 [TBL] [Abstract][Full Text] [Related]
8. The Role of Tocilizumab in Glucocorticoid Resistant Giant Cell Arteritis: A Case Series and Literature Review. Stretton B; Tan Y; Hassall M; Simon S J Neuroophthalmol; 2023 Mar; 43(1):91-95. PubMed ID: 36166708 [TBL] [Abstract][Full Text] [Related]
9. The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis. Jogimahanti AV; Kini AT; Irwin LE; Lee AG J Neuroophthalmol; 2021 Sep; 41(3):342-350. PubMed ID: 34415267 [TBL] [Abstract][Full Text] [Related]
13. Relapses in giant cell arteritis: Updated review for clinical practice. Alba MA; Kermani TA; Unizony S; Murgia G; Prieto-González S; Salvarani C; Matteson EL Autoimmun Rev; 2024 Jun; 23(6):103580. PubMed ID: 39048072 [TBL] [Abstract][Full Text] [Related]
14. Giant cell arteritis with ocular involvement successfully treated with tocilizumab and very short-course glucocorticoids: A case report. Khanna RK; Hage R; Lecler A; Sene T; Vignal-Clermont C; Clavel-Refregiers G J Fr Ophtalmol; 2021 Apr; 44(4):481-484. PubMed ID: 33712335 [TBL] [Abstract][Full Text] [Related]
15. Current and emerging diagnosis tools and therapeutics for giant cell arteritis. González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S Expert Rev Clin Immunol; 2018 Jul; 14(7):593-605. PubMed ID: 29877748 [TBL] [Abstract][Full Text] [Related]
16. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. Monti S; Águeda AF; Luqmani RA; Buttgereit F; Cid M; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B RMD Open; 2019; 5(2):e001003. PubMed ID: 31673411 [TBL] [Abstract][Full Text] [Related]
17. [From pathogenesis of giant cell arteritis to new therapeutic targets]. Samson M; Bonnotte B Rev Med Interne; 2017 Oct; 38(10):670-678. PubMed ID: 28800947 [TBL] [Abstract][Full Text] [Related]
18. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Kötter I; Henes JC; Wagner AD; Loock J; Gross WL Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655 [TBL] [Abstract][Full Text] [Related]
19. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. Buttgereit F; Dejaco C; Matteson EL; Dasgupta B JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619 [TBL] [Abstract][Full Text] [Related]
20. The role of biologics in the treatment of giant cell arteritis. González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S Expert Opin Biol Ther; 2019 Jan; 19(1):65-72. PubMed ID: 30513026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]